FDA approves Piramal's Neuraceq imaging agent

FDA approved Neuraceq [18F]- florbetaben from Piramal Enterprises Ltd. (BSE:PEL; NSE:PEL) for PET imaging of the brain to estimate beta amyloid neuritic plaque density in adults with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. The European Commission approved Neuraceq -- a PET tracer labeled with fluorine 18 (F-18) that binds beta amyloid -- last month. Piramal acquired worldwide rights to PET imaging tracer assets, including Neuraceq, from Bayer AG (Xetra:BAYN). ...